This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Eric Pauwels Biography and Net Worth

Insider of PTC Therapeutics

Eric Pauwels serves as Chief Business Officer of the Company. Mr. Pauwels has 34 years of healthcare experience in biopharmaceuticals and medical devices. Mr. Pauwels joined the Company in March 2015 as Senior Vice President and General Manager of the Americas. He also serves as a director of a subsidiary of PTC. From September 2011 until March 2015, Mr. Pauwels was the Chief Commercial Officer and President of International for NPS Pharmaceuticals, a publicly traded biopharmaceutical company that was acquired by Shire plc. In 2011, Mr. Pauwels was the Chief Marketing Officer of Accuray Inc. From 2005 to 2010 Mr. Pauwels served as the first Chief Commercial Officer for the Shire Rare Disease Business. Mr. Pauwels earned his B.S. from California State Polytechnic University in Pomona, California.

What is Eric Pauwels' net worth?: The estimated net worth of Eric Pauwels is at least $2.84 million as of April 17th, 2024. Mr. Pauwels owns 67,694 shares of PTC Therapeutics stock worth more than $2,840,440 as of November 20th. This net worth evaluation does not reflect any other assets that Mr. Pauwels may own. Additionally, Mr. Pauwels receives an annual salary of $847,670.00 as Insider at PTC Therapeutics. Learn More about Eric Pauwels' net worth.
How old is Eric Pauwels?: Mr. Pauwels is currently 63 years old. There are 6 older executives and no younger executives at PTC Therapeutics. The oldest executive at PTC Therapeutics is Dr. Allan Steven Jacobson Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director, who is 78 years old. Learn More on Eric Pauwels' age.
What is Eric Pauwels' salary?: As the Insider of PTC Therapeutics, Inc., Mr. Pauwels earns $847,670.00 per year. There are 2 executives that earn more than Mr. Pauwels. The highest earning executive at PTC Therapeutics is Dr. Stuart W. Peltz Ph.D., Co-Founder, Senior Consultant & Member of Scientific Advisory Board, who commands a salary of $1,540,000.00 per year. Learn More on Eric Pauwels' salary.
How do I contact Eric Pauwels?: The corporate mailing address for Mr. Pauwels and other PTC Therapeutics executives is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at [email protected]. Learn More on Eric Pauwels' contact information.
Has Eric Pauwels been buying or selling shares of PTC Therapeutics?: Eric Pauwels has not been actively trading shares of PTC Therapeutics during the last ninety days. Most recently, Eric Pauwels sold 787 shares of the business's stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $25.14, for a transaction totalling $19,785.18. Following the completion of the sale, the chief executive officer now directly owns 67,694 shares of the company's stock, valued at $1,701,827.16. Learn More on Eric Pauwels' trading history.
Who are PTC Therapeutics' active insiders?: PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Pierre Gravier (CFO), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Emma Reeve (Director), Michael Schmertzler (Director), David Southwell (Director), Dawn Svoronos (Director), Christine Utter (CAO), Alethia Young (Chief Financial Officer, Bicycle Therapeutics), and Jerome Zeldis (Director). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?: During the last twelve months, PTC Therapeutics insiders bought shares 1 times. They purchased a total of 7,700 shares worth more than $198,737.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 56,906 shares worth more than $1,787,917.16. The most recent insider tranaction occured on July, 16th when CFO Pierre Gravier sold 2,269 shares worth more than $77,191.38. Insiders at PTC Therapeutics own 5.5% of the company. Learn More about insider trades at PTC Therapeutics.
Information on this page was last updated on 7/16/2024.

Eric Pauwels Insider Trading History at PTC Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/17/2024	Sell	787	$25.14	$19,785.18	67,694
1/8/2024	Sell	1,569	$28.64	$44,936.16	46,612
4/18/2023	Sell	732	$52.04	$38,093.28	64,805
1/31/2023	Sell	375	$45.63	$17,111.25	65,537
1/24/2023	Sell	359	$47.45	$17,034.55	65,912
4/19/2022	Sell	822	$42.52	$34,951.44	49,772
2/1/2022	Sell	367	$40.00	$14,680.00
1/25/2022	Sell	359	$39.31	$14,112.29
4/19/2021	Sell	786	$48.17	$37,861.62	35,701
1/5/2021	Sell	1,067	$62.37	$66,548.79	26,587
11/3/2020	Sell	6,194	$56.50	$349,961.00	27,647

Eric Pauwels Buying and Selling Activity at PTC Therapeutics

PTC Therapeutics Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $41.96

$38.26

$42.79

50 Day Range

MA: $38.72

$32.27

$44.87

2 Week Range

Now: $41.96

$20.75

$46.98

Volume

722,545 shs

Average Volume

766,640 shs

Market Capitalization

$3.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad

Click here and I’ll tell you everything you need to know.

Eric Pauwels Biography and Net Worth

What is Eric Pauwels' net worth?

How old is Eric Pauwels?

What is Eric Pauwels' salary?

How do I contact Eric Pauwels?

Has Eric Pauwels been buying or selling shares of PTC Therapeutics?

Who are PTC Therapeutics' active insiders?

Are insiders buying or selling shares of PTC Therapeutics?